Login / Signup

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.

Hyung L KimPing LiHuei-Chung HuangSamineh DeheshiTara MartiBeatrice KnudsenHatem Abou-OufRidwan AlamTamara L LotanLucia L C LamMarguerite du PlessisElai DavicioniNeil FleshnerBrian R LaneAshley E RossJohn W DavisJames L MohlerBruce J TrockEric E KleinJeffrey J TosoianM Eric HyndmanTarek A Bismar
Published in: Prostate cancer and prostatic diseases (2018)
Decipher can be applied to prostate biopsies from NCCN-very-low/low and favorable-intermediate risk patients to predict absence of adverse pathologic features. These patients are predicted to be good candidates for active surveillance.
Keyphrases
  • prostate cancer
  • ejection fraction
  • newly diagnosed
  • squamous cell carcinoma
  • emergency department
  • neoadjuvant chemotherapy
  • chronic kidney disease